Investors Alert: Deadline Approaching in QuidelOrtho Corporation Class Action Lawsuit

Investors who have acquired shares of QuidelOrtho Corporation QDEL are alerted to the fast-approaching deadline of June 11, 2024, set for the submission of lead plaintiff motions in a class action lawsuit. Respected law firm Glancy Prongay & Murray LLP (GPM) is issuing a reminder concerning this critical date. The lawsuit has been filed on behalf of QuidelOrtho investors and pertains to alleged securities law violations.

About QuidelOrtho Corporation

QuidelOrtho Corporation, headquartered in San Diego, California, is at the forefront of developing, manufacturing, and distributing diagnostic testing solutions. Their diverse product portfolio addresses a vast array of health concerns, including infectious disease, cardiology, thyroid issues, general and women's health, eye health, gastrointestinal conditions, and toxicology, catering to a global clientele.

Legal Proceedings Explained

The class action lawsuit was initiated because of alleged misleading statements and potential wrongful acts that may have induced investors to purchase shares under false pretenses, resulting in financial losses. Shareholders of QDEL who have faced monetary damages from this situation are advised to be well informed about their rights, which includes the possibility of acting as a lead plaintiff.

Significance of the Lead Plaintiff Deadline

June 11, 2024, stands as a critical date for QDEL investors. To become a lead plaintiff, an individual must file their motion by this deadline. It is imperative to note that this is not a mandatory action for shareholders; however, it allows them to play a more significant role in the litigation process. The lead plaintiff, who is typically the investor with the largest financial interest, represents the class of shareholders during the lawsuit.

Investor, ClassAction, Deadline